About this episode

Dr. Ashwin Singh Parihar discusses with Dr. Louise Emmett the role of Lutetium - 177 PSMA SPECT / CT in predicting survival in metastatic castration resistant prostate cancer.

Dr. Ashwin Singh Parihar sits down with Dr. Louise Emmett to discuss how post-therapy Lutetium - 177 PSMA SPECT / CT may help predict overall survival in patients with metastatic castration resistant prostate cancer and shape future treatment decisions. Drawing from the ENZA -p trial run by ANZUP cancer trials group, they explore quantitative imaging, treatment response assessment, adaptive dosing strategies, and the growing role of theranostics in precision oncology. 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Ayati et al. Radiology 2026; 319(1):e252672.

People in this episode

Host: Dr. Ashwin Singh Parihar

Guest: Dr. Louise Emmett

Topics covered

• prostate cancer
• theranostics
• precision oncology
• quantitative imaging
• treatment response assessment
• adaptive dosing strategies

Keywords

• Lutetium-177
• PSMA SPECT/CT
• metastatic castration resistant prostate cancer
• ENZA-p trial
• treatment decisions
• theranostics
• precision oncology

Mentioned in this episode

Organizations: ANZUP cancer trials group

Books & works: 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer, Ayati et al. Radiology 2026; 319(1):e252672

More episodes of Radiology Podcast | RSNA

• How CT-based Screening Is Redefining Prevention · July 21, 2026 · 17 min
• Optimizing Radiography Utilization · July 14, 2026 · 35 min
• Finding the Value in AI Assistance · June 30, 2026 · 23 min
• Radiology Careers (re-release) · June 23, 2026 · 39 min
• The Future of Crohn Disease Detection · June 9, 2026 · 16 min
• Ultra-processed Foods and Muscle Fat · June 2, 2026 · 20 min

Explore listener stats, chart rankings, contacts and more on the Radiology Podcast | RSNA podcast page.